EMAIL THIS PAGE TO A FRIEND

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research

The effects of calcium supplementation on verified coronary heart disease hospitalization and death in postmenopausal women: a collaborative meta-analysis of randomized controlled trials.


PMID 25042841

Abstract

Calcium supplementation, particularly with vitamin D, has been an approved public health intervention to reduce fracture risk. Enthusiasm for this intervention has been mitigated by meta-analyses suggesting that calcium supplementation with or without vitamin D increases myocardial infarction (MI) risk; however, concern has been raised over the design of these meta-analyses. We, therefore, undertook a meta-analysis of randomized controlled trials with placebo or no-treatment control groups to determine if these supplements increase all-cause mortality and coronary heart disease (CHD) risk including MI, angina pectoris and acute coronary syndrome, and chronic CHD verified by clinical review, hospital record, or death certificate in elderly women. The Cochrane Central Register of Controlled Trials, MEDLINE, and EMBASE databases were searched from January 1, 1966, to May 24, 2013, for potentially eligible studies, reference lists were checked, and trial investigators were contacted where additional unpublished data were required. The search yielded 661 potentially eligible reports of which 18 met the inclusion criteria and contributed information on 63,563 participants with 3390 CHD events and 4157 deaths. Two authors extracted the data independently with trial data combined using random-effects meta-analysis to calculate the relative risk (RR). Five trials contributed CHD events with pooled relative RR of 1.02 (95% confidence interval [CI], 0.96-1.09; p = 0.51). Seventeen trials contributed all-cause mortality data with pooled RR of 0.96 (95% CI, 0.91-1.02; p = 0.18). Heterogeneity among the trials was low for both primary outcomes (I(2)  = 0%). For secondary outcomes, the RR for MI was 1.08 (95% CI, 0.92-1.26; p = 0.32), angina pectoris and acute coronary syndrome 1.09 (95% CI, 0.95-1.24; p = 0.22) and chronic CHD 0.92 (95% CI, 0.73-1.15; p = 0.46). In conclusion, current evidence does not support the hypothesis that calcium supplementation with or without vitamin D increases coronary heart disease or all-cause mortality risk in elderly women.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

50553
α-tri-Calcium phosphate, Reagent for transient & stable DNA transfections
Ca3O8P2
53737
α-tri-Calcium phosphate, puriss. p.a., ≥75% α-phase basis (sinterted powder)
Ca3O8P2
13204
β-tri-Calcium phosphate, puriss. p.a., ≥98% β-phase basis (unsintered powder)
Ca3O8P2
49963
β-tri-Calcium phosphate, puriss. p.a., ≥98% β-phase basis (sintered Powder)
Ca3O8P2
C4830
Calcium carbonate, BioXtra, ≥99.0%
CCaO3
C5929
Calcium carbonate, BioReagent, suitable for insect cell culture, ≥99.0%
CCaO3
481807
Calcium carbonate, 99.999% trace metals basis
CCaO3
202932
Calcium carbonate, ≥99.995% trace metals basis
CCaO3
398101
Calcium carbonate, ACS reagent, chelometric standard, 99.95-100.05% dry basis
CCaO3
310034
Calcium carbonate, powder, ≤30 μm particle size, 98%
CCaO3
21061
Calcium carbonate, BioUltra, precipitated, ≥99.0% (KT)
CCaO3
31208
Calcium carbonate, puriss. p.a., ≥99%
CCaO3
21067
Calcium carbonate, certified reference material for titrimetry, certified by BAM, according to ISO 17025, ≥99.5%
CCaO3
21069
Calcium carbonate, tested according to Ph.Eur.
CCaO3
PHR1326
Calcium carbonate, Pharmaceutical Secondary Standard; Certified Reference Material
CCaO3
1086403
Calcium Carbonate (AS), United States Pharmacopeia (USP) Reference Standard
CCaO3
C9756
Cholecalciferol, ≥98% (HPLC)
C27H44O
C9774
Cholecalciferol, analytical standard
C27H44O
C1357
Cholecalciferol, meets USP testing specifications
C27H44O
C2100000
Cholecalciferol, European Pharmacopoeia (EP) Reference Standard
C27H44O
1131009
Cholecalciferol, United States Pharmacopeia (USP) Reference Standard
C27H44O
47763
Cholecalciferol (D3), analytical standard
C27H44O
PHR1237
Cholecalciferol (Vitamin D3), Pharmaceutical Secondary Standard; Certified Reference Material
C27H44O
C2150000
Cholecalciferol for system suitability, European Pharmacopoeia (EP) Reference Standard
C27H44O
740292
Vitamin D3 solution, 100 μg/mL in ethanol, 97% (CP)
C27H44O
V-025
Vitamin D3 solution, 1 mg/mL in ethanol, ampule of 1 mL, certified reference material
C27H44O